research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
Search
for
Sort by
Research
960-990 / 1000+ results research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta‐Analysis
Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
research Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
CD8+ T cells are involved in alopecia areata and may cause disease relapse.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration
Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
research Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV
A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
research Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
Chemotherapy and cytokine therapy can cause various skin reactions, including hair loss and hypersensitivity.
research Plerixafor Biases CXCR4 Signaling Through β-Arrestin to Promote Melanogenesis via β-Catenin–MITF Activation
Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Targeting Endogenous Wnt Antagonists for Therapy Development in AGA: a Focus on DKKs and sFRPs
research 306 Effect of Cellular Blood Components on Chemotherapy Induced Alopecia
Mononuclear cells may protect against certain chemotherapy-induced hair loss.
research Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
research Supplementary Material for: Immunotherapy-Induced Scarring Alopecia: A Case Series
Immune therapy for cancer can cause hair loss scars in some patients.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research ODAC Votes No on IntraDose Injectible Cisplatin/Epinephrine Gel for Head and Neck Cancer
The committee decided not to approve the drug due to low effectiveness and high risks.
research Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
research Paclitaxel/Platinum combination regimen and alopecia
Most patients experienced significant but reversible hair loss during treatment.
research Squamous epithelial proliferation induced by walleye dermal sarcoma retrovirus cyclin in transgenic mice
The Walleye dermal sarcoma virus cyclin causes excessive skin cell growth in mice.
research Anticancer effects of metformin on neuroendocrine tumor cells in vitro
Metformin may help treat neuroendocrine tumors.
research PROTECTION AGAINST CYTOSINE ARABINOSIDE-INDUCED ALOPECIA BY MINOXIDIL IN A RAT ANIMAL MODEL
Minoxidil helps prevent hair loss from chemotherapy in rats.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Cyclohex-1-ene Carboxylic Acids: Synthesis and Biological Evaluation of Novel Inhibitors of Human 5α Reductase
Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
research Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study
The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
research Loose anchoring of anagen hairs and pili torti due to erlotinib
Erlotinib can cause hair loss and texture changes.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.